Vivos Therapeutics (VVOS) Current Assets (2019 - 2026)

Vivos Therapeutics (VVOS) has reported Current Assets for 8 consecutive years, with $4.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Assets fell 37.4% year-over-year to $4.2 million in Q2 2026; TTM through Jun 2026 was $4.2 million, a 37.4% decrease from a year earlier, with the FY2025 full-year figure at $4.4 million, down 41.34% from the prior year.
• Current Assets was $4.2 million for Q2 2026 at Vivos Therapeutics, down from $4.8 million in the prior quarter.
• Over five years, Current Assets peaked at $21.6 million in Q1 2022 and troughed at $2.0 million in Q3 2023.
• A 5-year average of $7.0 million and a median of $5.6 million in 2022 frame the typical range for Current Assets.
• Across the five-year window, Current Assets slumped 80.15% in 2022 and surged 272.75% in 2024, its largest moves.
• Over 5 years, Current Assets stood at $5.4 million in 2022, then tumbled by 54.63% to $2.5 million in 2023, then jumped by 203.66% to $7.5 million in 2024, then tumbled by 41.34% to $4.4 million in 2025, then retreated by 3.9% to $4.2 million in 2026.
• The last three Current Assets figures came in at $4.2 million (Q2 2026), $4.8 million (Q1 2026), and $4.4 million (Q4 2025), per Business Quant data.